Abstract
Alzheimers disease (AD) represents one of the most common ailments afflicting the rapidly growing elderly segment of todays population. Despite the vast amount of effort expended in developing a cure, currently approved drugs address only cognitive symptoms that, although important for improving a patients daily living standard, do not provide a significant delay or halt to disease progression. Early reports that individuals taking anti-inflammatory medications reduce their risk of developing AD has led to the "inflammation hypothesis" of AD and the subsequent testing of these drugs in the clinic. Tests of a select few of these medications in AD clinical trials have, however, yielded disappointing results. Reports of statin-based medications reducing the risk of AD have also led to the testing of this class of drugs in the clinic. Recently, the approval of the NMDA receptor antagonist memantine (Namenda®) has provided clinical support for glutamatergic processes in the disease and generated a renewed interest in the role of excitatory amino acids in the etiology of AD. In this review, we take a closer look at these three compelling areas for addressing AD therapeutics: inflammation, cholesterol, and glutamate. We present arguments that these components are interconnected and mutually regulate processes involved in AD progression. Special focus is given to inflammation as a central feature of AD that may be acting in synergy with cholesterol and glutamate to mediate the observed pathophysiology.
Keywords: glutamate, statins, inflammation, cholesterol, Alzheimer, ’, s disease
Current Pharmaceutical Design
Title: Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimers Disease
Volume: 12 Issue: 6
Author(s): G. E. Ringheim and A. M. Szczepanik
Affiliation:
Keywords: glutamate, statins, inflammation, cholesterol, Alzheimer, ’, s disease
Abstract: Alzheimers disease (AD) represents one of the most common ailments afflicting the rapidly growing elderly segment of todays population. Despite the vast amount of effort expended in developing a cure, currently approved drugs address only cognitive symptoms that, although important for improving a patients daily living standard, do not provide a significant delay or halt to disease progression. Early reports that individuals taking anti-inflammatory medications reduce their risk of developing AD has led to the "inflammation hypothesis" of AD and the subsequent testing of these drugs in the clinic. Tests of a select few of these medications in AD clinical trials have, however, yielded disappointing results. Reports of statin-based medications reducing the risk of AD have also led to the testing of this class of drugs in the clinic. Recently, the approval of the NMDA receptor antagonist memantine (Namenda®) has provided clinical support for glutamatergic processes in the disease and generated a renewed interest in the role of excitatory amino acids in the etiology of AD. In this review, we take a closer look at these three compelling areas for addressing AD therapeutics: inflammation, cholesterol, and glutamate. We present arguments that these components are interconnected and mutually regulate processes involved in AD progression. Special focus is given to inflammation as a central feature of AD that may be acting in synergy with cholesterol and glutamate to mediate the observed pathophysiology.
Export Options
About this article
Cite this article as:
Ringheim E. G. and Szczepanik M. A., Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimers Disease, Current Pharmaceutical Design 2006; 12 (6) . https://dx.doi.org/10.2174/138161206775474215
DOI https://dx.doi.org/10.2174/138161206775474215 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development and Validation of a RP-HPLC Method for Simvastatin Capsules
Current Pharmaceutical Analysis Unmet Needs in Schizophrenia
CNS & Neurological Disorders - Drug Targets Discussion on Pharmacogenetic Interaction in G6PD Deficiency and Methods to Identify Potential Hemolytic Drugs
Cardiovascular & Hematological Disorders-Drug Targets Advances in Development of Phosphatidylinositol 3-Kinase Inhibitors
Current Medicinal Chemistry Family Psychoeducation in Clinical High Risk and First-Episode Psychosis
Adolescent Psychiatry Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives
Current Vascular Pharmacology Mediterranean Diet And Longevity: An Example Of Nutraceuticals?
Current Vascular Pharmacology Novel Methods of Genetic Modification of Human Pluripotent Stem Cells
Recent Patents on Regenerative Medicine Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review
Reviews on Recent Clinical Trials Neonatal Ultrasound in Transport
Current Pediatric Reviews Xenosensors CAR and PXR at Work: Impact on Statin Metabolism
Current Drug Metabolism Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors
Current Topics in Medicinal Chemistry Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design Intravascular Targeting of a New Anticoagulant Heparin Compound
Cardiovascular & Hematological Disorders-Drug Targets Nocturnal Blood Pressure Abnormalities in Obstructive Sleep Apnea - Clinical Predictors
Current Respiratory Medicine Reviews The Developing Role of Neuregulin1 In Cardiac Regenerative Stem Cell Therapy
Current Pharmaceutical Design Jean-Baptiste de Sénac’s (1693-1770) Important Work on Cardiology and Valvular Disorders
Current Pharmaceutical Design Rapid Screening of Antioxidant Active Constituents from Puerariae Lobatae Radix Based on the Investigation of Quantitative Patteren-Activity Relationship
Current Analytical Chemistry Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Prospectives of Antihypertensive Nano-ceuticals as Alternative Therapeutics
Current Drug Targets